Introduction
============

Acute leukemia is the most common neoplasm in children; it is responsible for 25-30%of cancer cases in under 15-year-old children^([@r01])^. Despite the advances in treatment and supportive care, disease-free survival at five years remains between 35 and 60%^([@r01],[@r02])^. For patients with high-risk disease and for those who present disease relapse, hematopoietic stem cell transplantation (HSCT) is the curative alternative^([@r03],[@r04])^.

After HSCT, the total lymphocyte count returns to normal in approximately 3 months. However, the normal amount of T and B cells, in particular T CD4^+^ cells, is only reached at around 12 months after HSCT^([@r05])^.

In the early period after HSCT, the number of natural killer (NK) cells rises rapidly, and these represent the majority of mononuclear cells in the peripheral blood. NK cells are responsible for the early graft-versus-leukemia effect and slow recovery is related to increased risk of disease relapse^([@r06])^.

Some studies have shown the importance of early lymphocyte recovery (LR) after HSCT and its correlation with survival, lower relapse rates and lower transplant-related mortality (TRM)^([@r07]-[@r09])^.

The objective of this study was to evaluate the importance of the lymphocyte count on Days +30 and +100 after transplant as predictors of relapse and survival in pediatric patients submitted to HSCT for acute leukemia.

Methods
=======

Patients
--------

A total of 141 under 21-year-old patients with acute leukemia were submitted to HSCT between April 1995 and December 2008. Of these, 137 patients survived over 30 days and were included in this analysis. The patients\' ages varied from 1 to 20 years with a median of 9 years. Forty-eight patients (35%) were female and 89 (65%) were male. Eighty-one patients (59%) had acute lymphoblastic leukemia(ALL) and 56 patients (41%) had acute myeloid leukemia (AML).Patients transplanted in first and second clinical remission we reconsidered as having early disease (n = 82; 60%) and those with disease in third remission or higher, refractory disease or relapse, were considered as having advanced disease (n = 55; 40%).

Donors, stem cell source and conditioning regimens
--------------------------------------------------

Seventy-one patients (52%) received transplants from related donors and 66 patients (48%) had non-related donors;103 patients received bone marrow cells (75%) and 34 umbilical cord blood (25%). The conditioning regimens were busulfan + cyclophosphamide (Bu/CY; n = 34; 25%), total body irradiation + cyclophosphamide (TBI/CY; n = 69; 50%), TBI/CY + antithymocyte immunoglobulin (TBI/CY/ATG; n = 33; 24%)and others (fludarabine/CY and CY/ATG; n = 2; 1%). Prophylaxis of graft-versus-host disease (GVHD) was by methotrexate + cyclosporine (MTX/CsA; n = 98; 71%), cyclosporine + corticosteroid (CsA + CTC; n = 25; 18%), cyclosporine only (CsA; n = 9; 7%) and cyclosporine + MTX + corticosteroid(CsA/MTX/CTC; n = 5; 4%).

Definitions
-----------

LR was evaluated by the total lymphocyte count in peripheral blood on Days +30 and +100 after HSCT. Patients with lymphocyte counts (LC) lower than 0.3 x 10^9^/L on Day +30 and lower than 0.75 x 10^9^/L on Day +100 were considered as having inadequate LR. The cutoff value of 0.3 x 10^9^/L was chosen based on published studies^([@r08],[@r10])^ and the cutoff value of 0.75 x 10^9^/L was chosen as it was the median lymphocyte count on Day +100.

HLA compatibility was evaluated based on the characteristics of the class I and II antigens of the major histocompatibility complex in A, B (low resolution) and DRB1 (high resolution) loci. Patients and donors were considered entirely compatible when the antigens were the same in all six loci (6/6 compatibility).

Engraftment was confirmed by the cell count in the peripheral blood (neutrophils: absolute count over 0.5 x 10^9^/L for three consecutive days; Platelets: absolute count higher than 20 x 10^9^/L for three consecutive days without the need of transfusion for seven days).

Only patients with neutrophil engraftment were evaluated for the occurrence of acute graft-versus-host disease (GVHD) and only patients who survived with engraftment for more than 100 days were evaluated for chronic GVHD.

Acute GVHD was defined according to previously published clinical and laboratorial criteria^([@r11])^ and classified as Stage I to IV. Chronic GVHD was classified as limited or extensive according to the classification criteria proposed in 1980^([@r12])^.

The occurrence of death in the first 100 days after HSCT due to any cause except relapse of the disease was considered transplant-related mortality (TRM).

The Overall Survival (OS) was calculated from the day of HSCT until death by any cause and the relapse-free survival (RFS) was calculated from the day of HSCT until disease relapse or death by any cause, whichever came first.

Statistical analysis
--------------------

The Kaplan Meier method was used to analyze the OS and RFS. The log rank test was used for univariate analysis and Cox regression for multivariate analysis with variables that presented a p-value \< 0.2 in the univariate analysis being included. Death without engraftment and the death in remission were used as competitive risk factors in the evaluation of the cumulative incidences of engraftment and relapse. Mortality due to relapse was used as a competitive risk factor in the analysis of the cumulative incidence of TRM. The Gray method was used to compare the cumulative incidence curves. The multinomial logistic regression was used in the analysis of the factors that influenced LR on Day+30 and on Day +100.

A level of significance of 5% (p-value \< 0.05) and a power of 80% were used in the analysis. The SPSS (Statistical Package for the Social Sciences) and STATA 11 programs were used to perform statistical analysis.

Results
=======

Patient characteristics
-----------------------

The characteristics of patients according to LR are summarized in [Table 1](#t01){ref-type="table"}.

###### 

Patient characteristics according to lymphocyte recovery on Day +30

                                                                   **Lymphocyte recovery Day +30** \< 0.3 x 10^9^/L n (%)   **Lymphocyte recovery Day +30** ≥ 0.3 x 10^9^/L n (%)   **p-value\* chi-square test**           
  --------------------------- ------------------------------------ -------------------------------------------------------- ------------------------------------------------------- ------------------------------- ------- ---
  **Gender**                                                                                                                                                                                                        NS      
                              Female                               17 (31)                                                                                                          31 (38)                                  
                              Male                                 38 (59)                                                                                                          51 (62)                                  
  **Age**                                                                                                                                                                                                           0.034   
                              ≥ 9 year old                         24 (44)                                                                                                          52 (63)                                  
                              \< 9 year old                        31 (56)                                                                                                          30 (37)                                  
  **Diagnosis**                                                                                                                                                                                                     NS      
                              ALL                                  34 (62)                                                                                                          47 (57)                                  
                              AML                                  21 (38)                                                                                                          35 (43)                                  
  **Disease status**                                                                                                                                                                                                0.007   
                              Early disease                        30 (54)                                                                                                          26 (32)                                  
                              Advanced disease                     25 (46)                                                                                                          56 (68)                                  
  **Stem cell source**                                                                                                                                                                                              0.008   
                              Cord blood                           21 (38)                                                                                                          13 (16)                                  
                              Bone marrow                          34 (62)                                                                                                          69 (84)                                  
  **Donor x compatibility**                                                                                                                                                                                         NS      
                              Related compatible                   20 (36)                                                                                                          43 (52)                                  
                              Related with incompatibilities       2 (1)                                                                                                            6 (7)                                    
                              Non-related compatible               11 (20)                                                                                                          17 (21)                                  
                              Non-related with incompatibilities   22 (43)                                                                                                          16 (20)                                  

ALL: acute lymphocyte leukemia; AML: myeloid leukemia; NS: non-significant

Engraftment and GVHD analysis
-----------------------------

Complete engraftment was achieved by 117 patients (85%). Of the others, seven patients had only partial engraftment (5%) and 13 patients had primary graft failure (10%).

One hundred and twenty-four patients had neutrophilic engraftment and were included in the acute GVHD analysis and of these, 56 patients (41%) had acute GVHD, 30 (53%) at Stage III-IV. Chronic GVHD was evaluated in 112 patients that survived over 100 days with engraftment; 25 patients (22%) presented chronic GVHD with extensive disease in 14 patients (56%).

Global and relapse-free survival analysis
-----------------------------------------

The 3-year OS was 47%, with a median of 1169 days (range:181-4760 days), as demonstrated in [Figure 1](#f01){ref-type="fig"}. In the multivariate analysis, the factors related to worse OS were: inadequate LR on Days +30 and +100 and advanced disease at the time of HSCT ([Table 2](#t02){ref-type="table"}).

![Three-year overall survival](rbhh-34-430-g01){#f01}

###### 

Nominal Logistic regression

                                        **Lymphocyte recovery Day +30**   **Lymphocyte recovery Day +100**                            
  ------------------------------------- --------------------------------- ---------------------------------- ------------------------ ---
  Age (≤ 9 vs. \> 9 year old)           0.01 (2.23; 1.11-4.49)                                               0.3 (0.64; 0.28-1.49)     
  Diagnosis (ALL vs. AML)               0.59 (1.2; 0.6-2.42)                                                 0.01 (3.24; 1.12-11.6)    
  Donor (related vs. non-related)       0.03 (2.22; 1.10-4.47)                                               0.04 (2.10; 1.08-4.79)    
  Disease status (early vs. advanced)   0.02 (2.58; 1.27-5.23)                                               0.6 (1.18; 0.51-2.73)     
  Stem cell source (CB vs. BM)          0.008 (0.30; 0.13-0.68)                                              0.58 (1.32; 0.47-3.71)    
  ATG use (Yes vs. no)                  0.62 (1.12; 0.56-2.62)                                               0.03 (2.61; 1.06-7.06)    

OR: Odds ratio; 95% CI: 95% confidence interval; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; CB: Cord blood; BM: bone marrow; ATG: antithymocyte globulin

p-value \< 0.05 denotes significant difference

The 3-year RFS was 39% ([Figure 2](#f02){ref-type="fig"}). After the transplant, 56 patients presented disease relapse, with a median time to relapse of 135 days (Range: 28-1273 days). The cumulative incidence of relapse at 3 years was 45% as shown in [Figure 3](#f03){ref-type="fig"}. In the multivariate analysis,the factors that negatively influenced RFS were an inadequate LR at Day +100 and advanced disease at the time of HSCT.

![Three-year relapse-free survival](rbhh-34-430-g02){#f02}

![Cumulative incidence of relapse](rbhh-34-430-g03){#f03}

Seventy-three patients evolved to death in a median of 166 days after HSCT (range: 31-1650 days). The main causes of death were: disease relapse, infection and acute GVHD. Twenty patients evolved to death in the first 100 days after transplant with the cumulative incidence of TRM being 17% ([Figure 4](#f04){ref-type="fig"}). The causes of TRM were: infection (13 patients), acute GVHD (4 patients), veno-occlusive disease (2 patients) and engraftment failure (1 patient).

![Cumulative incidence of transplant-related mortality on Day +100](rbhh-34-430-g04){#f04}

Patients transplanted with early disease presented better OS (61% vs. 27%, p-value = 0.001) and RFS (53% vs. 22%,p-value = 0,000) than patients transplanted with advanced disease.

Lymphocyte recovery on Day +30
------------------------------

The factors associated with inadequate LR on Day +30 were: HSCT from non-related donors (p-value = 0.03), umbilical cord blood transplant (p-value = 0.008), age less than 9 years old (p-value = 0.01) and advanced disease at the time of HSCT (p-value = 0.02) as shown in [Table 2](#t02){ref-type="table"}. In the multivariate analysis none of the variables impacted the LR on Day +30.

When the patients were stratified according to the donor type to perform the multivariate analysis, it was observed that in the group of transplanted patients with related donors, age less than 9 years old was the only factor with a negative influence on the LR on Day +30, however, among the patients that received the transplant from non-related donors, none of the factors had significant influence on LR on Day +30.

Patients with inadequate LR on Day +30 had worse OS and RFS ([Figure 5](#f05){ref-type="fig"}).

![Three-year A) overall survival and B) relapse-free survival based on lymphocyte recovery on Day +30](rbhh-34-430-g05){#f05}

The TRM was significantly higher in the group with inadequate LR on Day +30 ([Figure 6](#f06){ref-type="fig"}).

![Cumulative incidence of transplant-related mortality based on lymphocyte recovery on Day +30](rbhh-34-430-g06){#f06}

A significant difference in the cumulative incidence of relapse was not observed between the groups of LR on Day +30 (p-value = 0.4).

Additionally, there were no significant differences in the occurrence of infections between the groups or in the incidence of acute or chronic GVHD.

Lymphocyte recovery on Day +100
-------------------------------

One hundred and twelve patients that survived over 100 days after HSCT with complete engraftment were included in the analysis of LR on Day +100. The characteristics of these patients are shown in [Table 3](#t03){ref-type="table"}.

###### 

Patient characteristics according to lymphocyte recovery on Day +100

                                                                   **Lymphocyte recovery Day +100** \< 0.75 x 10^9^/L   **Lymphocyte recovery Day +100** ≥ 0.75 x 10^9^/L   **p-value\* chi-square test**           
  --------------------------- ------------------------------------ ---------------------------------------------------- --------------------------------------------------- ------------------------------- ------- ---
  **Gender**                                                                                                                                                                                                NS      
                              Female                               10 (30)                                                                                                  26 (33)                                  
                              Male                                 23 (70)                                                                                                  53 (67)                                  
  **Age**                                                                                                                                                                                                   NS      
                              ≥ 9 year old                         21 (64)                                                                                                  42 (53)                                  
                              \< 9 year old                        12 (36)                                                                                                  37 (47)                                  
  **Diagnosis**                                                                                                                                                                                             0.006   
                              ALL                                  25 (76)                                                                                                  38 (48)                                  
                              AML                                  8 (24)                                                                                                   41 (52)                                  
  **Disease status**                                                                                                                                                                                        NS      
                              Early disease                        13 (40)                                                                                                  28 (35)                                  
                              Advanced disease                     20 (60)                                                                                                  51 (65)                                  
  **Stem cell source**                                                                                                                                                                                      NS      
                              Cord blood                           6 (18)                                                                                                   18 (23)                                  
                              Bone marrow                          27 (82)                                                                                                  61 (77)                                  
  **Donor x compatibility**                                                                                                                                                                                 NS      
                              Related compatible                   12 (36)                                                                                                  42 (53)                                  
                              Related with incompatibilities       2 (6)                                                                                                    6 (8)                                    
                              Non-related compatible               11 (33)                                                                                                  18 (23)                                  
                              Non-related with incompatibilities   8 (15)                                                                                                   13 (16)                                  

ALL: acute lymphocyte leukemia; AML: myeloid leukemia; NS: non-significant

The variables that negatively influenced the LR on Day +100 were: diagnosis of ALL (p-value = 0.01), transplant from non-related donor (p-value = 0.04) and conditioning regimen containing antithymocyte immunoglobulin (p-value = 0.03) as shown in [Table 2](#t02){ref-type="table"}. In the multivariate analysis, none of the factors influenced LR on Day +100.

When the patients were stratified according to donor type, it was observed that patients of non-related donors, had ALL as the only factor that negatively influenced the LR on Day +100 in the multivariate analysis, however, of the patients that received transplants from non-related donors, none of the factors significantly affected the LR on Day +100.

Patients with inadequate LR on Day +100 presented statistically lower OS (p-value = 0.05) and RFS (p-value = 0.01; [Figure 7](#f07){ref-type="fig"}). Furthermore, the cumulative incidence of relapse was significantly higher for the group with inadequate LR (p-value = 0.006) as shown in [Figure 8](#f08){ref-type="fig"}.

![Three-year A) overall survival and B) relapse-free survival based on lymphocyte recovery on Day +100](rbhh-34-430-g07){#f07}

![Cumulative incidence of relapse based on lymphocyte recovery on Day +100](rbhh-34-430-g08){#f08}

Discussion
==========

Data analysis shows that it is possible to obtain good survival rates in patients transplanted in the early stage of leukemia and that the main factor related to patient survival is the disease status at the time of HSCT. Patients transplanted in an early stage of the disease had a better overall survival (61% vs. 27% in 3 years); this data is similar to the published literature^([@r13],[@r14])^.

An early LR has been described as an important factor related to disease relapse in acute leukemia patients^([@r07],[@r08])^. However, in this study significant differences in relapse were not observed between groups. It is believed that some confounding factors may be related to this different result as this is a retrospective study, with great sample variability, including patients transplanted at different times and using different techniques.

It was observed that the patients who presented inadequate LR on Day +30 evolved with worse OS and RFS. This data is compatible with what has been observed in previous studies^([@r07],[@r08],[@r10])^.

Patients with inadequate LR on Day +30 presented worse RFS, however, no significant difference in the incidence of relapse was observed. This can be explained by the fact that early deaths, that occurred more frequently in the group with inadequate LR on Day +30, were included in the RFS analysis.

Previous studies report a higher TRM in inadequate LR patients^([@r07],[@r09])^. This study correlates this data, as a significantly higher incidence of TRM occurred in patients with inadequate LR on Day +30. This higher incidence of TRM is probably related to the higher vulnerability of the group with inadequate LR since, at this stage, some patients still do not have complete engraftment and have significant immune deficiency. The main cause of death in patients with TRM was infection.

On analyzing the LR on Day +100, significantly higher OS and RFS are seen in patients with lymphocyte counts ≥ 0.75 x 10^9^/L besides a lower cumulative relapse rate. This shows the importance of adequate LR in the initial period after HSCT.

It is known that the most commonly used method to evaluate immune recovery after HSCT is through immunophenotyping; the role of CD8^+^ and NK cell recovery is well known in the occurrence of relapse, mortality and infections^([@r15])^.

Considering that the patients present NK cell recovery within the first 30 days after HSCT^([@r05],[@r16])^ and CD8^+^ lymphocyte recover in around 2 or 3 months after HSCT, it can be assumed that patients who did not have adequate LR on Day +100 did not have adequate recovery of these cells. However, a parallel evaluation of the lymphocyte count and immunophenotyping of the peripheral blood would be necessary to prove this hypothesis.

To better evaluate the influence of LR on the relapse and survival of patients, a prospective evaluation of a more homogenous group with parallel analysis of the LR through immunophenotyping would be necessary. However, the findings of the current study serve as a warning to pay more attention to patients with inadequate LR on Days +30 and +100 after HSCT.

Conclusions
===========

An analysis of LR may be useful to predict OS and RFS after HSCT, however the evaluation of the LR on Day +30 was not a good predictor of relapse after HSCT.

The TRM was significantly higher in patients with inadequate LR (\< 0.3 x 10^9^/L) on Day +30 after HSCT.

Regarding the LR on Day +100 after HSCT, there was a higher cumulative incidence of relapse and lower OS and RFS in patients with inadequate LR (\< 0.75 x 10^9^/L).
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